The Lancet Psychiatry published ”Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial” on 1-6-16. This study focuses on assessing the long term benefits of CBT as an adjunctive treatment to “the usual and customary medication” prescribed by PCPs for patients whose depression has not responded to antidepressants.
The study followed patients 469 patients for 3-5 years, and concluded:
CBT as an adjunct to usual care that includes antidepressants is clinically effective and cost effective over the long-term for individuals whose depression has not responded to pharmacotherapy. In view of this robust evidence of long-term effectiveness and the fact that the intervention represented good value-for-money, clinicians should discuss referral for CBT with all those for whom antidepressants are not effective.
This article comes to our attention courtesy of the prolific posting service provided by Ken Pope, Ph.D. It provides strong support for the value of CBT and the benefits of coordinating care between PCPs and therapists.
Therapists could use this information when marketing their services to PCPs.